Florida Research Consortium

1
Florida Research Consortium

• Phytoneutraceuticals as
• Immunostimulators for Immunity
• James Rogers, J.D., M.S. (Presenter)
• Herman Friedman, Ph.D, Distinguished Professor
• Tech Transfer Conference
• Hilton Walt Disney World, Orlando FL
• May 18-19, 2005

2
Phytonutraceuticals
Phyto Plant derived
Neutraceutical Any substance that is a food or
a part of a food and provides medical or health
benefits, including the prevention and treatment
of disease.
3
Green Tea is one of the most widely investigated
phytonutraceuticals
30-42 of the dry weight of solids in brewed
green tea is composed of polyphenols, of which
epigallocatechin-3-gallate (EGCG) is the most
abundant. These compounds are generally knows as
tea catechins.
4
_______________________________
5
Cancer Inhibition
U.S. Patent No. 6,652,890 November 25,
2003 Morre et al., Tea Catechins as cancer
specific proliferation inhibitors
6
Antibacterial Activity
U.S. Patent No. 5,879,683 March 9,
1989 Hamilton-Miller Antibacterial agent
containing tea extract or active fraction thereof
and beta-lactam antibiotic
7
Delivery of Therapeutic Agents
U.S. Patent No. 6,562, 864 May 13,
2003 Larson Catechin multimers as therapeutic
drug Delivery targets
8
Treatment of Skin Conditions
U.S Patent Publication No. 20030175234 Steven
Hernandez et al. Use of polyphenols to treat
skin conditions
9
Weight Loss
U.S. Patent Publication No. 20020192308 John
Mamana Method and composition for controlling
weight
10
Immunostimulators
?
11
The Technology

• Novel compositions of catechins
• Methods of use of such compositions
• for immunostimulation

12
Target Industries

• Food and Dietary (catechin compositions as immune
  boosting supplements)
• Drug (catechin formulations either with or
  without other drug formulations)

13
Technology Advantages

• Catechins are extremely low in toxicity and well
  tolerated by humans, even at high doses
• Catechins are inexpensive to produce

14
Immunosupression
Viruses (e.g., colds)
Catechin
Bacteria
Stress
15
Potential Commercial Impact

• Who will buy this technology?
• People suffering from immune suppression brought
  on by colds, stress, cigarette smoke, etc.

16
Scientific TeamUSF College of
MedicineDepartment of Medical Microbiology and
Immunology

• Dr. Herman Friedman, Distinguished Professor
• Dr. Friedman has over 40 years directing
  research in immunology and microbiology
• Experienced in partnerships with companies and
  investors
• Flexible and business minded

17
Experiments in Mice
Bacteria counts high
Bacteria infection

Bacteria infection EGCG
Macrophages
Nicotine
Bacteria counts low
Cytokine modulation important for host resistance
to bacteria infection Reversal or attentuation
of immunosupression ?
Catechins
Dendritic cells
18
Technology Status

• Current stage of development
• In vitro studies of catechin effects on immune
  cells
• Intellectual Property Status
• Institutional Disclosure
• Commercialization activity
• None

19
What is Next?

• In vivo studies in animal models (mice dogs) in
  combination with in vitro studies to look for
  novel compositions
• Patenting
• Funds needed to complete next phase 100,000
• Technology is not ready to leave University
  (still in research stage)

20
Point of Contact

• Herman Friedman, Ph.D.
• Hfriedma_at_hsc.usf.edu
• University South Florida College Medicine
• [phone]